Angielski
This is an important book which examines renal cell carcinoma. Integrating scientific developments and therapeutic innovations over the past decade, this book offers physicians treating kidney cancer and researchers with latest information related to the epidemiology, biology and treatment of renal cell carcinoma. The book is a compilation of contributions from experts in their respective fields across the world. Contributing specialists have presented reviews about current knowledge in the management of both metastatic and localized renal cell carcinoma and also the current advances in, imaging, immune dysfunction and molecular genetics associated with the diseases. Special emphasis has been laid on the biology of selected target molecules and several agents which inhibit these targets, covering topics devoted to pharmaceutical drugs that selectively inhibit receptor tyrosine kinases (axitinib and sunitinib). Researchers, kidney cancer patients and urological physicians will find this book highly beneficial in their research and practice.
